Stevens Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Stevens Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,142	Closed	-$201K	–	1093
2016 Q3	$201K	Buy	+8,142	New	+$184K	0.01%	808
2016 Q2	–	Sell	-16,135	Closed	-$246K	–	1119
2016 Q1	$246K	Sell	16,135 -55,483	-77%	-$724K	0.01%	718
2015 Q4	$963K	Buy	71,618 +28,563	+66%	+$442K	0.04%	425
2015 Q3	$604K	Buy	+43,055	New	+$801K	0.03%	482
2015 Q1	–	Sell	-30,115	Closed	-$250K	–	1224
2014 Q4	$250K	Buy	+30,115	New	+$253K	0.01%	783
2014 Q2	–	Sell	-32,948	Closed	-$295K	–	1297
2014 Q1	$295K	Buy	+32,948	New	+$303K	0.01%	795

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stevens Capital Management's SUPN Position: Q4 2016 in Review

Stevens Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 8,142 shares — an estimated $201K sold.

Stevens Capital Management first reported a position in SUPN in Q1 2014 and held it in 6 quarters. The position peaked at $963K in Q4 2015. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

Stevens Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Stevens Capital Management sold 8,142 Supernus Pharmaceuticals shares in Q4 2016, an estimated $201K.
Stevens Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Stevens Capital Management's Supernus Pharmaceuticals position peaked at $963K in Q4 2015.
233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on Stevens Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.